Journal ArticleDOI
Reslizumab in Eosinophilic Asthma: A Review.
Emma D. Deeks,Guy Brusselle +1 more
TLDR
Adding intravenous reslizumab to the current asthma therapy of patients with eosinophilic asthma inadequately controlled with inhaled corticosteroids resulted in significant reductions in clinical asthma exacerbation frequency and significant improvements in lung function, asthma control and health-related quality of life relative to adding placebo.Abstract:
Reslizumab (Cinqaero®; Cinqair®) is a humanized monoclonal antibody against interleukin-5 (IL-5), a cytokine mediator of eosinophilic airway inflammation. Reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the BREATH phase III clinical trial programme. In three double-blind BREATH studies of up to 52 weeks’ duration, adding intravenous reslizumab (3 mg/kg, once every 4 weeks) to the current asthma therapy of patients (aged 12–75 years) with eosinophilic asthma inadequately controlled with inhaled corticosteroids resulted in significant reductions in clinical asthma exacerbation frequency and significant improvements in lung function, asthma control and health-related quality of life relative to adding placebo. Pooled data from the two trials of 52 weeks’ duration indicated similar benefits with reslizumab across various patient subgroups, including patients with severe eosinophilic asthma. Reslizumab was generally well tolerated, with very few recipients experiencing severe or serious treatment-related adverse events. Moreover, in an open-label extension study, continued use of reslizumab for up to 2 years was associated with durable lung function benefit, without any new tolerability concerns. Thus, intravenous reslizumab extends the valuable add-on treatment options for adults with severe eosinophilic asthma inadequately controlled with standard therapies.read more
Citations
More filters
Journal ArticleDOI
Targeting Cytokines as Evolving Treatment Strategies in Chronic Inflammatory Airway Diseases.
TL;DR: A review of the current understanding of the roles of cytokines in the pathophysiology of chronic inflammatory airway diseases is presented and outcomes of clinical trials in cytokine blockade as novel treatment strategies for selected patient populations with those diseases will be discussed.
Journal ArticleDOI
Advances in understanding and reducing the burden of severe asthma in children.
TL;DR: Detailed assessment and characterisation of each child with seemingly severe asthma is necessary so that the most effective and appropriate management strategy can be implemented.
Journal ArticleDOI
The role of eosinophils in chronic spontaneous urticaria
Sabine Altrichter,Stefan Frischbutter,Jie Shen Fok,Jie Shen Fok,Jie Shen Fok,Pavel Kolkhir,Pavel Kolkhir,Qingqing Jiao,Qingqing Jiao,Per Stahl Skov,Martin Metz,Martin K. Church,Marcus Maurer +12 more
TL;DR: A new picture of an important role of eosinophils in the pathogenesis of CSU is emerging, and treatments aimed at reducing eOSinophil accumulation and activation, such as the anti-IL-5 antibodies mepolizumab, resl Lizumab and benralizumAB, have been reported to reduce CSU symptoms.
Journal ArticleDOI
Eosinophils: Friends or Foes?
TL;DR: Evidence has emerged that eosinophils play a major role in the modulation of allergic inflammation and in the repair of damaged tissues in diseases characterized by eosInophilic infiltration, and there is strong evidence that although all the beneficial roles of eosINophils have yet to emerge, eos inophils must be considered friends and not foes.
Journal ArticleDOI
Cytokine Storm and Mucus Hypersecretion in COVID-19: Review of Mechanisms
Mohsin Ali Khan,Zaw Ali Khan,Mark Rector Charles,Pushpendra Pratap,Abdul Naeem,Zainab Siddiqui,Nigar Naqvi,Shikha Srivastava +7 more
TL;DR: In this paper, the role of cytokine storm in inducing sudden mucus hypersecretion in COVID-19 was discussed and active constituents that inhibit or activate several potential targets are outlined for further research.
References
More filters
Journal ArticleDOI
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
Mario Castro,James Zangrilli,Michael E. Wechsler,Eric D. Bateman,Guy Brusselle,Philip G. Bardin,Kevin R. Murphy,Jorge Maspero,C.D. O'Brien,Stephanie Korn +9 more
TL;DR: These results support the use of reslizumab in patients with asthma and elevated blood eosinophil counts who are inadequately controlled on inhaled corticosteroid-based therapy.
Journal ArticleDOI
Reslizumab for Poorly Controlled, Eosinophilic Asthma: A Randomized, Placebo-Controlled Study
Mario Castro,Sameer K. Mathur,Frederick E. Hargreave,Louis-Philippe Boulet,Fang Xie,James B. Young,H. Jeffrey Wilkins,Timothy Henkel,Parameswaran Nair +8 more
TL;DR: Patients receiving reslizumab showed significantly greater reductions in sputum eosinophils, improvements in airway function, and a trend toward greater asthma control than those receiving placebo.
Journal ArticleDOI
Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma - A pilot study 164/rccm.200206-5250C
Johan Kips,Brian J. O'Connor,Stephen J. Langley,Ashley Woodcock,Huib A. M. Kerstjens,Dirkje S. Postma,Mel Danzig,Francis Cuss,Romain Pauwels +8 more
TL;DR: It is concluded that SCH55700 is a biologically active anti-human IL-5 antibody that can be safely used in severe steroid-treated asthma and its therapeutic potential needs to be addressed in specifically designed efficacy trials.
Journal ArticleDOI
Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study
TL;DR: Reslizumab improved lung function, asthma control and symptoms, and quality of life and was well tolerated in patients with inadequately controlled asthma (despite standard therapy) and elevated blood eosinophil levels.
Journal ArticleDOI
Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts
TL;DR: Rlizumab was well tolerated in patients with inadequately controlled asthma, with fewer overall adverse events compared with placebo and Clinically meaningful effects on lung function and symptom control were not seen in patients unselected for baseline eosinophils.